{
    "data": [
        {
            "id": "58669",
            "type": "article",
            "attributes": {
                "publishOn": "2007-12-31T05:23:18-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Several High Quality Drugs in the Developmental Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23899",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/58669-gilead-sciences-several-high-quality-drugs-in-the-developmental-pipeline"
            }
        },
        {
            "id": "57315",
            "type": "article",
            "attributes": {
                "publishOn": "2007-12-14T04:21:16-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "YM BioSciences: YMI Trading Below Cash?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20831",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/57315-ym-biosciences-ymi-trading-below-cash"
            }
        },
        {
            "id": "50915",
            "type": "article",
            "attributes": {
                "publishOn": "2007-10-23T07:00:27-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Continues To Shine, But Watch The Competition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20923",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/50915-gilead-continues-to-shine-but-watch-the-competition"
            }
        },
        {
            "id": "50559",
            "type": "article",
            "attributes": {
                "publishOn": "2007-10-19T07:30:18-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Tops Estimates, Sees Strong FY Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20181",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/50559-gilead-sciences-tops-estimates-sees-strong-fy-sales"
            }
        },
        {
            "id": "48980",
            "type": "article",
            "attributes": {
                "publishOn": "2007-10-05T04:09:55-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pharmasset's Hepatitis C Drug Has A Promising Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20678",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "84571",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/48980-pharmassets-hepatitis-c-drug-has-a-promising-future"
            }
        },
        {
            "id": "40586",
            "type": "article",
            "attributes": {
                "publishOn": "2007-07-10T09:30:41-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "More Bullish Calls on Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20454",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "84166",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/40586-more-bullish-calls-on-gilead-sciences"
            }
        },
        {
            "id": "40395",
            "type": "article",
            "attributes": {
                "publishOn": "2007-07-08T10:46:48-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Shares Still Have 20-25% Upside - Barron's",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20278",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "84148",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "4445",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/40395-gilead-sciences-shares-still-have-20minus-25-percent-upside-barrons"
            }
        },
        {
            "id": "38830",
            "type": "article",
            "attributes": {
                "publishOn": "2007-06-19T23:27:00-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Receives FDA Approval For Pulmonary Arterial Hypertension Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20876",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/38830-gilead-receives-fda-approval-for-pulmonary-arterial-hypertension-drug"
            }
        },
        {
            "id": "32749",
            "type": "article",
            "attributes": {
                "publishOn": "2007-04-19T05:58:38-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Posts 55% Q1 Profit Rise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/32749-gilead-posts-55-percent-q1-profit-rise"
            }
        },
        {
            "id": "31930",
            "type": "article",
            "attributes": {
                "publishOn": "2007-04-10T15:37:56-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Versant: YM Biosciences Now a 'Speculative Buy'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/31930-versant-ym-biosciences-now-a-speculative-buy"
            }
        },
        {
            "id": "31385",
            "type": "article",
            "attributes": {
                "publishOn": "2007-04-03T15:04:45-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Rapid Growth Expected From New Products",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20422",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "83528",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/31385-gilead-sciences-rapid-growth-expected-from-new-products"
            }
        },
        {
            "id": "24439",
            "type": "article",
            "attributes": {
                "publishOn": "2007-01-18T03:10:04-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eye on Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20422",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "83115",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/24439-eye-on-gilead-sciences"
            }
        }
    ]
}